Cite
HARVARD Citation
Ettl, J. et al. (2018). Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of oncology. pp. 1939-1947. [Online].